---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Phase of product development"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Phase of product development. Topics: Regulatory status: Under review; NDA submitted December 2025, PDUFA target action date December 2026; Commercial launch preparation: launch planned upon approval, no date stated; FDA acceptance of the NDA, March 2026; NDA submission, December 2025; 7 further topics. 12 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Summary

Mineralys Therapeutics submitted a New Drug Application (NDA) for lorundrostat to the FDA in December 2025 for “the treatment of hypertension in combination with other antihypertensive drugs”. The FDA accepted the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026. The company described the application as still under review in its third quarter 2026 results announcement and in its release on the Transform-HTN results presented on November 8, 2026. According to the company, the NDA includes the pivotal Launch-HTN (phase 3) and Advance-HTN (phase 2) trials, the Explore-CKD proof-of-concept trial, and the Transform-HTN open-label extension trial; the Explore-OSA trial was not part of the original application. In its 2026 Form 10-Q, the company described an advisory committee meeting as “not anticipated currently”. No FDA expedited program designation and no marketing application outside the United States was found. The company has stated no launch date; it describes its commercial preparations as on track for “launch upon approval”. In its third quarter 2025 results announcement, the company had planned the submission for “near the end of 2025 or during the first quarter of 2026”.

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm); [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for); [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial); [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from); [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript); [Mineralys Therapeutics second quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/111/mineralys-therapeutics-reports-second-quarter-2026); [Mineralys Therapeutics third quarter 2025 results announcement (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial)

<a id="topic-2.1.1-2"></a>

### Regulatory status: Under review; NDA submitted December 2025, PDUFA target action date December 2026

> “Lorundrostat is currently under review by the U.S. Food and Drug Administration for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “The U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

> “We submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat.”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

> “Based on the positive results from our pivotal program, we submitted an NDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.1-3"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

### Commercial launch preparation: launch planned upon approval, no date stated

> “As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval,”
> “The Company is advancing its commercial launch preparations and now has an expanded medical affairs team and sales force in place.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

> “While the FDA continues its review of the NDA, our focus is on completing our launch preparations so that we are ready to reach patients soon after the potential approval of lorundrostat.”

Source: [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)

> “We are delighted to welcome Kris and Lonnel to our Board of Directors as we prepare for the potential approval and commercial launch of lorundrostat for the treatment of uncontrolled or resistant hypertension,”

Source: [Mineralys Therapeutics press release, board appointments (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/122/mineralys-therapeutics-expands-its-board-of-directors-with)

> “PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval”
> “The Company expects to have the sales organization established in advance of the anticipated PDUFA target date.”

Source: [Mineralys Therapeutics second quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/111/mineralys-therapeutics-reports-second-quarter-2026)

<a id="topic-2.1.1-5"></a>

### FDA acceptance of the NDA, March 2026

> “announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-2.1.1-6"></a>

### NDA submission, December 2025

> “Mineralys filed an NDA for lorundrostat to the U.S. Food and Drug Administration (FDA) in late 2025.”

Source: [Mineralys Therapeutics press release, corporate update (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/89/mineralys-therapeutics-provides-corporate-update-and)

> “We also ended the year with the submission of our first NDA for the treatment of hypertension in adults.”

Source: [Mineralys Therapeutics fourth quarter 2025 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/94/mineralys-therapeutics-reports-fourth-quarter-2025)

<a id="topic-2.1.1-7"></a>

### Trials included in the NDA

> “The NDA includes the positive data from the LAUNCH-HTN and ADVANCE-HTN pivotal trials, as well as the proof-of-concept trial EXPLORER-CKD and our open-label extension trial TRANSFORM-HTN.”
> “EXPLORER-OSA was not part of the original NDA application.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

> “The NDA submission included the diverse dataset the Company has built with lorundrostat across five positive clinical trials that demonstrated clinically meaningful blood pressure (BP) reduction, 24-hour control and a favorable safety profile in adults with uncontrolled or resistant hypertension.”
> “The Company’s ongoing open-label extension trial, which supported the NDA submission, enables participants to continue to receive lorundrostat and allows the Company to gather additional long-term safety and efficacy data.”

Source: [Mineralys Therapeutics first quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/100/mineralys-therapeutics-reports-first-quarter-2026-financial)

> “Ahead of the NDA submission in December 2025, we completed five successful clinical trials of lorundrostat supporting the efficacy and safety profile while also validating aldosterone as an integral therapeutic target in uHTN or rHTN. This includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial,”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.1-8"></a>

### Advisory committee meeting: not anticipated

> “conducting ongoing regulatory activities, including responding to FDA information requests, supporting a potential advisory committee meeting (not anticipated currently), preparing for potential approval and post-marketing commitments, and potential commercial launch of lorundrostat;”

Source: [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)

<a id="topic-2.1.1-9"></a>

### FDA expedited program designations (Fast Track, Breakthrough Therapy, Priority Review)

No evidence found.

<a id="topic-2.1.1-10"></a>

### Marketing applications outside the United States

No evidence found.

<a id="topic-2.1.1-11"></a>

### NDA submission planned for late 2025 or the first quarter of 2026, November 2025, superseded in December 2025

> “Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026”
> “These findings for lorundrostat will provide the foundation for an NDA submission which we anticipate submitting near the end of 2025 or during the first quarter of 2026,”

Source: [Mineralys Therapeutics third quarter 2025 results announcement (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial)

<a id="topic-2.1.1-12"></a>

### Pre-NDA feedback from the FDA, October 2025

> “We are at an exciting point in our company’s history as we prepare for our NDA submission following pre-NDA feedback from the FDA last month.”

Source: [Mineralys Therapeutics third quarter 2025 results announcement (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial)

<a id="topic-2.1.1-13"></a>

### Pivotal Launch-HTN and Advance-HTN topline results, March 2025

> “today announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-2.1.1-14"></a>

### Phase 2 Target-HTN topline results, November 2022

> “today announced topline results from the Phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension.”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

<a id="topic-2.1.1-15"></a>

### First-in-human study by Tanabe, November 2016 to May 2017

> “A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017) to determine the safety, tolerability, PK, and PD of single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
